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ABSTRACT:
Purpose: Single-agent EGFR inhibitor therapy is effective mainly in patients 
with lung cancer and EGFR mutations. Treating patients who develop resistance, 
or who are insensitive from the outset, often because of resistant mutations, other 
aberrations or the lack of an EGFR mutation, probably requires rational combinations. 
We therefore investigated the outcome of EGFR inhibitor-based combination regimens 
in patients with heavily-pretreated non-small cell lung cancer (NSCLC) referred to a 
Phase I Clinic.
Methods: We reviewed the electronic records of patients with NSCLC treated 
with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, 
cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or 
cetuximab and sirolimus. 
Results: EGFR mutations were detected in 16% of patients (21/131). EGFR 
inhibitor-based combination regimens were administered to 15 patients with EGFR-
mutant NSCLC and 24 with EGFR wild-type disease. Stable disease (SD) ≥6 months/
partial remission (PR) was attained in 20% of EGFR-mutant patients (3/15; two 
with sensitive mutations and secondary resistance to prior erlotinib, and one with 
a resistant mutation), as well as 26% of evaluable patients (5/19) with wild-type 
disease. One of three evaluable patients with squamous cell histology achieved SD 
for 26.5 months (EGFR wild-type, TP53-mutant, regimen=erlotinib, cetuximab and 
bevacizumab).
Conclusions: Eight of 34 evaluable patients (24%) with advanced, refractory 
NSCLC evaluable for response achieved SD ≥6 months/PR (PR=3; SD ≥6 months=5) 
on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, 
cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with 
secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type 
disease, and, squamous histology.
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INTRODUCTION
Activation of the epidermal growth factor receptor 
(EGFR) signaling pathway is known to play a significant 
role in the pathophysiology of non-small cell lung cancer 
(NSCLC)[1]. It may also be important in other tumors[2]. 
Aberrant activation of the signaling pathway may occur 
due to mutations in exons 18 through 21, which encode 
part of the tyrosine kinase domain and are bundled around 
the ATP-binding pocket of the enzyme[1-4]. There is 
a broad literature on the efficacy of EGFR inhibitors 
in NSCLC[3-6] .  Although many patients with EGFR-
mutant NSCLC respond to EGFR inhibitors initially, they 
eventually develop resistance to treatment.  Therefore, 
combination approaches to overcome resistance is an area 
of active clinical research[7, 8]. 
The role of EGFR inhibition in patients with wild-
type EGFR and lung cancer has been debated. Studies 
with erlotinib show increased survival in unselected 
patients with lung cancer,[9] though there is a general 
consensus that patients with sensitive EGFR mutations 
are most likely to benefit[3, 4]. Recently, preclinical 
studies have demonstrated that EGFR can signal via 
a kinase-independent pathway[10], suggesting a role 
for combining EGFR kinase inhibitors and antibodies. 
Furthermore, preclinical models suggest that several 
molecules synergize with EGFR inhibitors, including the 
multikinase inhibitor dasatinib[11] and the proteasome 
inhibitor bortezomib[12]. Herein, we report our experience 
with EGFR-based combination regimens in patients with 
advanced, heavily-pretreated NSCLC referred to a phase 
I clinic, including those with secondary resistance to 
erlotinib, resistant mutations, and EGFR wild-type disease. 
RESULTS
EGFR mutations
Twenty-one of 131 NSCLC patients (16%) tested 
had EGFR mutations. Twenty-five EGFR mutations were 
present in those 21 individuals. Four patients had two 
EGFR mutations. Ten of the 25 EGFR mutations were 
present in exon 19; three in exon 20; and, 12 in exon 21. 
Of the four patients who had two EGFR mutations, three 
of them had two EGFR mutations in exon 21 and 1 patient 
had an EGFR mutation in exon 19 and exon 20.  Deletions 
in exon 19 (n = 9) and the L858R substitution mutation 
in exon 21 (n = 7) were the two most common types of 
mutations. 
Treatment
Fifteen of the 21 patients (71%) with an underlying 
EGFR mutation were enrolled in five clinical trials that 
included an EGFR inhibitor combination (Patients and 
Methods and Table 2). 
Of the remaining six EGFR-mutant NSCLC 
patients, one patient was treated on a clinical trial that did 
not include an EGFR inhibitor, one patient was referred to 
hospice, one patient died soon after being seen, and three 
patients were treated with single-agent erlotinib by their 
primary oncologist or on study. 
Patients treated with EGFR inhibitor-based 
combinations
Patient characteristics of the 15 EGFR mutation-
positive and 24 EGFR wild-type NSCLC patients treated 
with EGFR inhibitor-based combination regimens are 
summarized in Table 1. 
Co-existing mutations in 15 EGFR-mutant 
patients treated with EGFR-based regimens
Simultaneous mutations in other genes were 
assessed when tissue was available. Two of seven EGFR 
mutation-positive patients (29%) assessed had a PIK3CA 
mutation. One patient (case #15, Table 2) had an E545K 
mutation in exon 9 of the PIK3CA gene in addition to the 
EGFR mutation (T847I in exon 21; unknown sensitivity 
to EGFR inhibitors). A second patient (case #5, Table 2) 
had an E542K mutation in exon 9 of the PIK3CA gene 
in addition to two known sensitive EGFR mutations 
(L858R and G873E) in exon 21. No patient that underwent 
treatment with an EGFR inhibitor-based combination had 
a KRAS mutation (though one patient who was not treated 
had a G12C mutation in addition to a resistant EGFR 
[D761N] mutation in exon 19).  
Other mutations in EGFR wild-type patients 
treated with EGFR-based regimens
Two of 13 patients (15%) with EGFR wild-type 
disease assessed for PIK3CA mutation had an E545K 
mutation in exon 9 of the PIK3CA gene (cases #15 and 23, 
Table 3).  Two of 20 patients (10%) with EGFR wild-type 
evaluated for KRAS mutation had a G12D mutation (cases 
#20 and 21, Table 3). Of the two patients with EGFR 
wild-type disease evaluated for TP53 mutation, one had 
an R196 mutation in exon 6 (case #1, Table 3) and the 
other had a V157F mutation in exon 5 (case #19, Table 3).
Responses to EGFR inhibitor-based combinations 
in EGFR-mutant NSCLC patients 
Three of 15 evaluable (20%) patients attained 
either PR (n=2; cases #2 and 5, Table 2) or SD ≥6 
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months (n=1; case #10, Table 2). Six patients came off 
study prior to post-treatment imaging evaluation due to 
clinical progression (all of whom were arbitrarily graphed 
as 20% progression in Figure 1). One patient (case #2, 
Table 2) achieved a PR (33% decrease; duration=13+ 
months) on erlotinib/cetuximab despite having a known 
EGFR-resistant mutation (insertion in exon 20)[13]. This 
patient had previously received two lines of standard 
chemotherapy but had not received prior EGFR inhibitor 
therapy. TTF on the last standard treatment before referral 
to phase I was 2.0 months. A second patient (case #5, 
Table 2) with two known EGFR-sensitive mutations 
(L858R and G873E in exon 21) and a PIK3CA mutation 
(E542K in exon 9) had a PR (55% decrease; duration=9+ 
months) on erlotinib/cetuximab/bevacizumab. This patient 
had received six lines of prior therapy including single-
agent erlotinib (TTF=14.3 months). TTF on the last 
standard treatment before referral was 4.5 months. A third 
patient (case #10, Table 2) with a known EGFR-sensitive 
mutation (L858R) in exon 21 attained SD for 10+ months 
on erlotinib/bortezomib. This patient had received six lines 
of prior therapy including single-agent erlotinib (TTF = 
5.5 months). TTF on the last standard treatment before 
referral was 5.9 months. 
Responses and TTF in EGFR-mutant patients 
who had received prior EGFR inhibitors
Of the 12 patients who had progressed previously 
on EGFR inhibitors and received an EGFR inhibitor-
based combination regimen after referral, two patients 
(17%) achieved either PR (n=1; case #5, Table 2; 
duration=9+ months) or SD≥6 months (n=1; case #10, 
Table 2; duration=10+ months) on this study. Of the three 
patients who achieved SD ≥6 months/PR on this study, 
two patients (67%; cases #10 and #5) had received prior 
erlotinib therapy as single-agent and had progressed. The 
TTF on the EGFR inhibitor-based combination therapies 
on this study is ongoing at 10+ and 9+ months vs. 5.5 and 
14.3 months respectively on prior single-agent erlotinib. 
For the 12 EGFR-mutant patients who received prior 
EGFR inhibitors,  median TTF on their EGFR inhibitor-
based combination regimen after referral was 2 months 
as compared to 8 months on a prior EGFR inhibitor 
(p=0.044)
Responses to EGFR inhibitor-based combinations 
in NSCLC patients with EGFR wild-type disease 
Of the 24 patients with EGFR wild-type disease 
(Table 3) treated on the same protocols as listed above, 
19 were evaluable for response to treatment. Five patients 
were not evaluable for response, as restaging had not 
yet occurred at the time of this analysis. Overall, 5 of 
19 evaluable patients (26%) had either a PR (n=1, case 
#12, Table 3; duration = 4.1 months) or SD ≥6 months 
(n=4; cases #1, 6, 9, and, 10; duration = 26.5 9.2, 6.5, 
and 11.0 months respectively). All of them were treated 
on erlotinib/cetuximab/bevacizumab. The median TTF 
of the 24 patients with EGFR wild-type disease treated 
Figure 1: 3-D Waterfall plot. Best response by RECIST, of 15 NSCLC patients with EGFR positive-mutations treated with an EGFR 
inhibitor-based regimen. Patients with clinical progression or with new metastases were graphed as 20% progression. Time to treatment 
failure in months is represented by solid lines and the arrow indicates that the patient was still on study when the data was censored. Patients 
with PIK3CA mutations in addition to EGFR mutation and patients who received prior EGFR inhibitor therapy are designated as such. 
Dotted horizontal line at -30% indicates border for partial response.
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Table 1: Baseline characteristics of 15 evaluable patients 
with EGFR mutation-positive NSCLC and 24 patients with 
EGFR wild-type NSCLC treated with EGFR inhibitor-based 
combination regimens
Variable EGFR-mutant n=15 EGFR wild-type n=24
Sex, n (%)
     Male 8 (53) 14 (58)
     Female 7 (47) 10 (42)
Age (years)
     Median 65 69
     Range 29-76 42-82
Ethnicity, n (%)
     Caucasian 6 (40) 21 (88)
     Asian 5 (33) 0 (0)
     Hispanic 2 (13) 2 (8)
     African American 2 (13) 1 (4)
Histology, n (%)
     Adenocarcinoma 13 (87) 20 (83)
     Squamous cell 1 (7) 3 (13)
     Adenosquamous 1 (7) 0 (0)
     Neuroendocrine 0 (0) 1 (4)
EGFR mutation, n (%)
     Exon 19 6 (40) 0 (0)
     Exon 20 2 (13) 0 (0)
     Exon 21 4 (27) 0 (0)
     Two mutations 3 (20) 0 (0)
KRAS mutation, n (%)
     Positive 0 (0) 2 (8)
     Negative 13 (87) 18 (75)
     Unknown 2 (13) 4 (17)
PIK3CA mutation, n (%)
     Positive 2 (13) 2 (8)
     Negative 5 (33) 11 (46)
     Unknown 8 (53) 11 (46)
History of smoking, n (%)
     Ex-smoker 7 (47) 16 (67)
     Never smoked 8 (53) 8 (33)
Number of prior therapies
     Median 4 2
     Range 0-7 1-7
Previous EGFR inhibitors, n (%)
     Yes 12 (80) 8 (33)
     No 3 (20) 16 (67)
ECOG PS
     0 4 (27) 5 (21)
     1 10 (67) 14 (58)
     2 1 (7) 5 (21)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, 
Epidermal Growth Factor Receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog; NSCLC, Non-Small Cell Lung Cancer; PS, Performance 
status; PIK3CA, Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; 
PR, Partial response; SD, Stable disease
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Table 2: Characteristics of 15 patients with EGFR mutations§ treated with EGFR inhibitor-based 
regimens 
Case 
No. Histology
EGFR 
mutations 
(exon)
Sensitive/
Resistant†
Concomitant 
mutations
Previous EGFR inhibitor 
therapy Treatment in phase I program
Yes/ No Best response
TTF 
(months) EGFR inhibitor 
Best 
response
TTF 
(months)
1 Adenocarcinoma
insertion/ 
deletion in 
exon 19 
Sensitive
PIK3CA: Not done* 
KRAS: No
TP53: Not done
Yes PR 24.8 erlotinib, dasatinib PD** 2
2 Adenocarcinoma insertion in exon 20 Resistant
PIK3CA: No 
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab PR 13+
3 Adenocarcinoma deletion in exon 19 Sensitive
PIK3CA:Not done 
KRAS: No
TP53: Not done
Yes SD 12.0
erlotinib, 
cetuximab, 
bevacizumab
SD 4
4 Adenocarcinoma deletion in exon 19 Sensitive
PIK3CA:Not done 
KRAS: No
TP53: Not done
Yes PR 26.1 erlotinib, cetuximab PD** 1
5 Adenocarcinoma
L858R (exon 
21), G873E 
(exon 21)
Sensitive, 
Sensitive
PIK3CA: 
E542K (exon 9) 
KRAS: No
TP53: Not done*
Yes SD 14.3
erlotinib, 
cetuximab, 
bevacizumab
PR 9+
6 Adenocarcinoma
D830Y 
(exon 21), 
V834A 
(exon 21)
Unknown 
significance 
Unknown 
significance
PIK3CA:No 
KRAS: No
TP53: Not done
Yes SD 4.0 cetuximab, sirolimus SD 4
7 Adenocarcinoma L858R (exon 21) Sensitive
PIK3CA:No 
KRAS: No
TP53: Not done
Yes PR 8.1 erlotinib, bortezomib SD 2
8 Adenocarcinoma
T790M 
(exon 20), 
deletion in 
exon 19 
Resistant, 
Sensitive
PIK3CA: Not done* 
KRAS: No
TP53: Not done
Yes PR 1.9 erlotinib, cetuximab PD** 2
9 Adenocarcinoma L858R (exon 21) Sensitive
PIK3CA:No 
KRAS: No
TP53: Not done
Yes SD 11.5 erlotinib, dasatinib PD 2
10 Adenocarcinoma L858R (exon 21) Sensitive
PIK3CA:Not done 
KRAS: No
TP53: Not done
Yes PR 5.5 erlotinib, bortezomib SD 10+
11 Adenocarcinoma insertion in exon 20 Resistant
PIK3CA: Not done*
KRAS: No
TP53: Not done
No NA NA
erlotinib, 
cetuximab, 
bevacizumab
SD 3
12 Adenocarcinoma deletion in exon 19 Sensitive
PIK3CA:No 
KRAS: No
TP53: Not done
Yes SD 3.5 cetuximab, sirolimus SD 4
13 Adenosquamous deletion in exon 19 Sensitive
PIK3CA: Not done* 
KRAS: Not done*
TP53: Not done*
Yes PR 3.4 erlotinib, cetuximab PD 1
14 Adenocarcinoma deletion in exon 19 Sensitive
PIK3CA:Not done 
KRAS: Not done
TP53: Not done
Yes SD 8.0 erlotinib, cetuximab PD** 2
15 Squamous cell carcinoma 
T847I (exon 
21)
Unknown 
significance
PIK3CA: 
E545K (exon 9) 
KRAS: No
TP53: Not done*
No NA NA erlotinib, dasatinib PD** 0.4
Abbreviations: EGFR, Epidermal Growth Factor Receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NA, Not applicable; NSCLC, 
Non-Small Cell Lung Cancer; PR, Partial response; PIK3CA, Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; PD, Progressive disease; SD, 
Stable disease; TTF, Time to treatment failure; TP 53, Tumor Protein p53
§ Of the remaining six EGFR-mutant NSCLC patients who were not treated on EGFR inhibitor-based regimens, two patients had a sensitive deletion in exon 
19, one patient had a resistant  D761N mutation in exon 19, one patient had 2 EGFR-sensitive mutations, L858R and L833V, in exon 21, and two patients 
had a sensitive L858R mutation in exon 21 
†Sensitive or resistant is denoted based on survey of the literature.
*not done because tissue was not available for molecular analysis
**clinical progression/new metastasis
+did not progress at the time of analysis
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on EGFR inhibitor-based combinations in phase I clinical 
trial program is statistically longer (3.3 months; 95% CI, 
1.2-5.4 months) compared to median TTF on last standard 
therapy (2.3 months; 95% CI, 1.8-2.8 months; p=0.045; 
Figure 3). Four of five patients with SD ≥6 months/PR had 
not received prior EGFR inhibitors. One patient (case #6, 
Table 3), who had previously received erlotinib as a single-
agent for 6.2 months and had progressed, had SD for 9.2 
months on erlotinib/cetuximab/bevacizumab. One of five 
patients who achieved SD ≥6 months/PR had squamous 
cell histology (case #1, Table 3; duration of SD=26.5 
months). Overall, two evaluable patients with EGFR wild-
type disease (cases #1 and 14, Table 3) who were treated 
with EGFR inhibitors had squamous histology.
Responses in NSCLC patients with squamous cell 
histology 
A total of three evaluable patients treated on EGFR 
inhibitor-based combinations had squamous cell histology, 
two of whom had EGFR wild-type disease (cases #1 and 
14, Table 3), and one of whom had an EGFR mutation 
(case #15, Table 2). One of the two patients with wild-
type EGFR (case #1, Table 3) attained SD for 26.5 
months on erlotinib/cetuximab/bevacizumab. This patient 
had received two lines of standard therapy, but was not 
previously treated with an EGFR inhibitor. TTF on the 
last standard therapy prior to this study was 2.4 months. 
A second patient with wild-type EGFR (case #14, Table 
3) had progressive disease after 2.1 months on erlotinib/
cetuximab/bevacizumab. This patient had received only 
one line of standard therapy (not an EGFR inhibitor) and 
the TTF was 4.2 months. The third patient was EGFR 
mutation-positive (case #15, Table 2; T847I, unknown 
sensitivity to EGFR inhibitors) and also had an additional 
PIK3CA mutation (E545K in exon 9); this patient had 
progressive disease within one month on erlotinib and 
dasatinib. This patient had received two lines of standard 
therapy, but not an EGFR inhibitor. TTF on last therapy 
before referral was 1.0 month.  
Responses in NSCLC patients with other 
simultaneous mutations 
PIK3CA:
Of the two EGFR mutation-positive patients with 
a simultaneous PIK3CA mutation, one patient (case 
#5, Table 2) with an E542K mutation in exon 9 of the 
PIK3CA gene in addition to two sensitive EGFR mutations 
(L858R and G873E in exon 21), achieved a PR (-55%) 
for 9+ months on erlotinib/cetuximab/bevacizumab. The 
other EGFR mutation-positive patient (T847I in exon 
21; unknown sensitivity to EGFR inhibitors) with a co-
existing E545K mutation in exon 9 of the PIK3CA gene 
(case #15, Table 2), had progressive disease in 0.4 months 
on erlotinib and dasatinib.  
Of the two EGFR wild-type NSCLC patients with 
a E545K mutation in exon 9 of the PIK3CA gene, one 
patient (case #15, Table 3) has ongoing SD at 3+ months 
on erlotinib/cetuximab/bevacizumab; the other patient 
(case #23, Table 3) had SD for 3 months on erlotinib/
dasatinib. 
KRAS/TP53: 
The two EGFR wild-type patients with a KRAS 
mutation (cases #20 and 21, Table 3) were not evaluable 
as they had not reached the post-treatment assessment. 
None of the 19 evaluable patients with EGFR wild-type 
had a KRAS mutation. Of the two EGFR wild-type patients 
with a TP53 mutation, one patient (case #1, Table 3) had 
prolonged SD for 26.5 months on erlotinib/cetuximab/
bevacizumab; the other patient (case #19, Table 3) had PD 
after 0.5 months on erlotinib/cetuximab. 
Figure 2: Computed tomography (CT) scans of a NSCLC patient (case #5, Table 2) with two sensitive EGFR mutations 
(L858R in exon 21 and G873E in exon 21) and a PIK3CA mutation (E542K in exon 9). a) CT at baseline, and b) CT taken 
5 months after treatment initiation with erlotinib/cetuximab/bevacizumab demonstrating a PR (-55%).  Duration of response = 9+ months. 
Patient had received prior erlotinib for 14.3 months.
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Table 3: Characteristics of 24 NSCLC patients with EGFR wild-type disease treated with 
EGFR inhibitor-based regimens 
Case 
Number Histology Other mutations
Previous EGFR inhibitor therapy Treatment in phase I program
Yes/No Best response TTF (months)
EGFR inhibitor-
based therapy
Best 
response
TTF 
(months)
1 Squamous cell carcinoma 
PIK3CA: No
KRAS: No
TP53: R196 (exon 6)
No NA NA erlotinib, cetuximab, bevacizumab SD 26.5
2 Adenocarcinoma
PIK3CA: Not done
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab, bevacizumab PD** 2.0
3 Adenocarcinoma
PIK3CA: Not done
KRAS: Not done
TP53: Not done
No NA NA erlotinib, cetuximab, bevacizumab PD** 0.9
4 Adenocarcinoma
PIK3CA: Not done*
KRAS: No
TP53: Not done
Yes PD 2.7 erlotinib, cetuximab, bevacizumab SD 4.1
5 Adenocarcinoma
PIK3CA: Not done
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab, bevacizumab SD 4.4
6 Adenocarcinoma
PIK3CA: No
KRAS: No
TP53: Not done
Yes SD 6.2 erlotinib, cetuximab, bevacizumab SD 9.2
7 Adenocarcinoma
PIK3CA: Not done
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab, bevacizumab PD 2.0
8 Adenocarcinoma
PIK3CA: Not done
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab, bevacizumab PD** 3.8
9 Adenocarcinoma
PIK3CA: No
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab, bevacizumab SD 6.5
10 Adenocarcinoma
PIK3CA: No
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab, bevacizumab SD 11.0
11 Adenocarcinoma
PIK3CA: Not done
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab, bevacizumab SD 2.2
12 Adenocarcinoma
PIK3CA: Not done*
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab, bevacizumab PR 4.1
13 Adenocarcinoma
PIK3CA: No
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab, bevacizumab SD 3.3
14 Squamous cell carcinoma 
PIK3CA: Not done
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab, bevacizumab PD 2.1
15 Adenocarcinoma
PIK3CA: E545K (exon 9)
KRAS: No
TP53: Not done*
No NA NA erlotinib, cetuximab, bevacizumab SD 3.1+
16 Adenocarcinoma
PIK3CA: Not done
KRAS: No
TP53: Not done
No NA NA erlotinib, cetuximab SD 2.0
17 Squamous cell carcinoma 
PIK3CA: No
KRAS: Not done*
TP53: Not done
Yes SD 6.0 erlotinib, cetuximab too early 1.5+
18 Adenocarcinoma
PIK3CA: No
KRAS: No
TP53: Not done
Yes PD** 0.7 erlotinib, cetuximab too early 1.6+
19 Adenocarcinoma
PIK3CA: No
KRAS: No
TP53: V157F (exon 5)
Yes PD** 0.9 erlotinib, cetuximab PD** 0.5
20 Adenocarcinoma
PIK3CA: No
KRAS: G12D
TP53: Not done*
Yes PD 2.3 erlotinib, cetuximab too early 0.0+
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Overall Survival
The median OS of 15 EGFR mutation-positive 
patients treated on EGFR inhibitor-based regimens from 
the date of start of therapy was 4.7 months (95% CI, 3.5 
– 5.9 months).The one year survival rate was 31% (95% 
CI, 22.3-41.1%). At the time of analysis, 12 of 15 patients 
were dead. The median OS of 24 EGFR wild-type patients 
treated on the same regimens was 3.8 months (95% CI, 
0.6-7.0 months).  
DISCUSSION
The identification of molecular aberrations and 
selection of therapy to ‘match’ these aberrations is gaining 
momentum as a preferred treatment approach[14-24].  In 
the Phase I setting, studies have sought to validate this 
approach across a range of mutation types, and to support 
broad genomic testing.  
EGFR mutations, frequently observed in patients 
with NSCLC, activate the kinase activity of EGFR, leading 
to upregulation of downstream survival pathways[25, 26]. 
In our study, EGFR mutations in exons 18-21 were present 
in 21 of 131 patients (16%) with NSCLC. Despite the 
dramatic initial responses to single-agent EGFR tyrosine 
kinase inhibitors (TKIs) in EGFR mutation-positive 
NSCLC patients, 70% of them relapse within one year of 
initiation of therapy[7, 8, 27]. It has been reported that 
kinase-independent activity of EGFR prevents autophagic 
cell death, perhaps accounting for progression of disease 
despite treatment with tyrosine kinase inhibitors [10]. It is 
conceivable that combining EGFR kinase inhibitors with 
EGFR antibody may therefore overcome resistance. Based 
on preclinical studies, other strategies to augment EGFR 
inhibition includes use of bortezomib in combination with 
EGFR kinase inhibitors due to its growth inhibitory and 
pro-apoptic effects on cancer cell lines[12] and dasatinib 
in combination with EGFR kinase inhibitor as in vitro data 
from NSCLC cell lines demonstrates that Src inhibition 
may enhance the antitumor activity of EGFR inhibition in 
the presence of EGFR mutations[11].
In our study, eight of 34 evaluable patients (23%) 
treated with EGFR inhibitor-based combinations 
achieved SD ≥6 months/PR.  Those individuals include 
EGFR mutation-positive patients with a de novo resistant 
mutation (n=1); EGFR mutation-positive (sensitive 
mutation) and prior secondary resistance to EGFR 
inhibitors (n=2); and, EGFR wild-type disease (n=5; 
including a patient with squamous cell histology).  
Figure 3: Kaplan-Meier estimates of time to treatment 
failure in 24 NSCLC patients with EGFR wild-
type disease treated with EGFR inhibitor-based 
combination therapies in phase I clinical trial program 
(3.3 months) vs. time to treatment failure on their last standard 
therapy (2.3 months; p=0.045; log-rank test)
21 Adenocarcinoma
PIK3CA: No
KRAS: G12D
TP53: Not done*
No NA NA erlotinib, cetuximab too early 0.1+
22 Adenocarcinoma
PIK3CA: No
KRAS: Not done
TP53: Not done
Yes PD** 0.8 erlotinib, bortezomib PD** 0.3
23 Neuroendocrine
PIK3CA: E545K (exon 9)
KRAS: Not done
TP53: Not done
No NA NA erlotinib, dasatinib SD 2.8
24 Adenocarcinoma
PIK3CA: Not done
KRAS: No
TP53: Not done
Yes PD 2.0 cetuximab, sirolimus too early 0.9+
Abbreviations: EGFR, Epidermal Growth Factor Receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NA, Not 
applicable; NSCLC, Non-Small Cell Lung Cancer; PR, Partial response; PIK3CA, Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; 
SD, Stable disease; PD, Progressive disease; TTF, Time to treatment failure; TP 53, Tumor Protein p53
*not done because tissue was not available for molecular analysis
**clinical progression/new metastasis
+did not progress at the time of analysis
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Of the 15 EGFR mutation-positive NSCLC patients 
treated on EGFR inhibitors, three (20%) had SD ≥6 
months/PR (cases #2, 5 and 10, Table 2). One patient 
with a known EGFR-resistant mutation (insertion in exon 
20; case #2, Table 2) has an ongoing PR (33% decrease) 
at 13+ months on therapy with erlotinib and the EGFR 
antibody cetuximab. Indeed, there is preclinical data 
demonstrating superiority when EGFR kinase inhibitors 
are combined with EGFR antibody in regard to antitumor 
effect[28, 29]
A second patient (case #5, Table 2) with two known 
EGFR-sensitive mutations (L858R and G873E in exon 21) 
attained a PR (55% decrease) for 9+ months on erlotinib/
cetuximab/bevacizumab. Interestingly, this patient 
also had a PIK3CA mutation (E542K in exon 9) in the 
downstream signaling pathway which is a known resistant 
mechanism to EGFR inhibition[30]. The PIK3CA mutation 
may explain why the patient had previously developed 
secondary resistance to single-agent erlotinib. Preclinical 
studies have demonstrated antitumor activity with PI3K/
mTOR inhibitor combinations in gefitinib-resistant 
PIK3CA-mutant NSCLC cell lines[31]. Clinical trials 
with dual blockade of PI3K and mTOR are underway[32, 
33]. The response seen in this patient on erlotinib/
cetuximab/bevacizumab may be due to synergistic effect 
of simultaneous EGFR and  vascular endothelial growth 
factor  (VEGF) inhibition, as demonstrated in preclinical 
models, including EGFR inhibitor-resistant cell lines[34] 
and in patients with metastatic colorectal cancer[35], 
and NSCLC[36, 37]. A third patient (case #10, Table 2) 
with a known EGFR-sensitive mutation (L858R), with 
previous response to single agent erlotinib and subsequent 
resistance, has ongoing SD (26% decrease) for 10+ 
months on erlotinib and bortezomib. There is preclinical 
evidence that dual blockade of proteasome activity and 
EGFR function by combining bortezomib plus cetuximab 
has synergistic antitumor activity[12].  Patients treated 
with erlotinib may also benefit from re-treatment[38], 
so this could also explain the observation of prolonged 
stable disease, at least in part. However, the TTF on prior 
erlotinib was 5.5 months, while the current TTF is 10+ 
months, suggesting that the longer current TTF could 
not be due to erlotinib alone. These observations indicate 
that combining treatment with drugs that target different 
signaling pathways may help patients who had progressed 
on single-agent targeted therapy after a period of initial 
response.
Unexpectedly, patients with EGFR wild-type 
disease were also noted to have salutary effects on 
EGFR inhibitor-based combination therapies. Five of 19 
evaluable NSCLC patients with wild-type EGFR treated 
on the same EGFR inhibitor-based regimens attained SD 
≥6 months/PR. The median TTF on EGFR inhibitor-based 
regimen (3.3 months) was significantly longer than the 
median TTF on their last standard therapy (2.3 months; 
p=0.045; Figure 3). These data suggest that EGFR-based 
combinations can be active in patients with wild-type 
disease[39, 40]. All these patients received erlotinib/
cetuximab/bevacizumab. Previously, modest antitumor 
activity has been reported in 4 of 13 NSCLC patients with 
wild-type EGFR (31%) on gefitinib and cetuximab[41]. 
We also noted anecdotal activity in patients with 
squamous cell histology. Of the three evaluable patients 
with squamous cell histology who were treated with EGFR 
inhibitor-based regimens, two patients had EGFR wild-
type disease (cases #1 and 14, Table 3) and one patient 
was EGFR-mutant (case #15, Table 2). One patient (TP53-
mutation positive; case #1, Table 3) with EGFR wild-type, 
squamous cell histology achieved SD for 26.5 months on 
erlotinib/cetuximab/bevacizumab after progression on 
two prior therapies. Limited data exists regarding patients 
with squamous cell histology treated with EGFR inhibitors 
because these patients typically have EGFR wild-type 
disease[42]. In one study [43], 121 patients with squamous 
cell carcinoma of the lung were treated with single-agent 
erlotinib. Thirty seven of 69 evaluable patients achieved 
PR/SD; however, the duration of response or molecular 
aberrations was unknown. In another study[44], 1,125 
NSCLC patients including 190 patients with squamous 
cell carcinoma were randomized to either chemotherapy 
alone or to cetuximab plus chemotherapy. A survival 
advantage was observed in 557 NSCLC patients treated 
with cetuximab plus chemotherapy; however, information 
on which of these responders had squamous cell histology 
was not reported. Finally, one responsive patient was 
noted to have a TP53 mutation. Recent retrospective data 
analysis posits longer progression-free survival for TP53-
mutant patients on bevacizumab-based regimens[45].
The activity noted in these subtypes of NSCLC 
is hypothesis-generating; however, sample size is a 
significant limitation of this study. The heterogeneity 
of combination treatments and the retrospective nature 
of the analysis must also be considered. Therefore, any 
interpretation of these results needs to be approached 
with caution. Furthermore, the antitumor activity seen 
in two patients with EGFR-mutant NSCLC (cases #5 
and 10, Table 2), who had progressed on prior treatment 
with erlotinib after initial response, may be due to the re-
treatment effect that occurs in patients with EGFR mutant 
disease with reintroduction of an EGFR tyrosine kinase 
inhibitor after a drug holiday[38]. However, in the latter 
case (case #10, Table 2), the TTF is ongoing and at least 
double the TTF on prior EGFR inhibitor therapy.  
In conclusion, this study demonstrated that treatment 
with EGFR inhibitor-based combination therapies was 
associated with SD ≥6 months/PR in subtypes of heavily 
pretreated advanced NSCLC not traditionally associated 
with response to EGFR inhibitors, including 1 of 2 patients 
with a de novo EGFR-resistant mutation; 2 of 12 patients 
(17%) with an EGFR-sensitive mutation and secondary 
EGFR resistance after a period of initial response; 5 of 19 
evaluable patients (26%) with EGFR wild-type disease; 
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and, 1 of 3 evaluable patients (25%) with squamous cell 
carcinoma. Further exploration of rational EGFR inhibitor 
combinations in a broad range of patients with NSCLC 
may be warranted. 
METHODS
Patients
We investigated the EGFR mutation status of 
131 consecutive patients with NSCLC referred to the 
Department of Investigational Cancer Therapeutics (Phase 
I Clinical Trials Program) at The University of Texas MD 
Anderson Cancer Center (MDACC) beginning January 
1, 2009. The study and all treatments were conducted 
in accordance with the guidelines of the MD Anderson 
Institutional Review Board. 
Tissue samples and mutation analyses
EGFR mutations were investigated in archival 
formalin-fixed, paraffin-embedded tissue blocks or 
material from fine needle aspiration biopsy obtained from 
diagnostic and/or therapeutic procedures. All histologies 
were centrally reviewed at MDACC. EGFR mutation 
testing was done in the Clinical Laboratory Improvement 
Amendment–certified Molecular Diagnostic Laboratory 
within the Division of Pathology and Laboratory Medicine 
at MDACC. 
DNA was isolated from formalin-fixed, paraffin-
embedded tissue by using a QIAmp DNA Minikit (Qiagen 
Inc., Valencia, CA) according to the manufacturer’s 
instructions. EGFR exons 18-21 sequence were analyzed 
in both sense and antisense directions for the presence of 
mutations using nested PCR followed by direct sequencing 
of the nested PCR amplicons. The nested-PCR was done 
using the primers and annealing conditions as described 
by Lynch et al[3]. The nested PCR amplicons were 
purified using the Qiagen QIAquick PCR Purification 
Kit, followed by cycle-sequencing using BigDye 
Terminator Kit v1.1 (ABI, Foster City, CA) on ABI Prism 
3130 Genetic Analyzer, according to manufacturer’s 
instructions. Whenever possible, in addition to EGFR, we 
tested for other mutations such as PIK3CA (codons 532 to 
554 in exon 9 and codons 1011 to 1062 in exon 20), KRAS 
(codons 12, 13, and 61) and TP53 (exons 4 to 9).
Treatment and evaluation
EGFR inhibitors included the small molecule 
inhibitor erlotinib and the antibody cetuximab.  Rationale 
for the trials was based on preclinical work demonstrating 
synergistic or additive effects and/or clinical work 
suggesting complementary pathway inhibition. The 
trials included erlotinib/cetuximab/bevacizumab 
(ClinicalTrials.gov identifier: NCT00543504); erlotinib/
cetuximab (ClinicalTrials.gov identifier: NCT00895362); 
erlotinib/bortezomib (ClinicalTrials.gov identifier: 
NCT00895687); erlotinib/dasatinib (ClinicalTrials.gov 
identifier: NCT00895128); and cetuximab/sirolimus 
(ClinicalTrials.gov identifier: NCT00940381). Treatment 
was chosen based on trial availability and physician and 
patient preference. Treatment continued until disease 
progression or unacceptable toxicity occurred.  Treatment 
was carried out according to the specific requirements of 
the treatment protocols selected. Assessments, including 
history, physical examination, and laboratory evaluations, 
were done as specified in each protocol, typically before 
the initiation of therapy, weekly during the first cycle, 
and then, at a minimum, at the beginning of each new 
treatment cycle. 
Response assessment
Efficacy was assessed from computed tomography 
(CT) scans and/or magnetic resonance imaging (MRI) and/
or positron emission tomography (PET) scan at baseline 
before treatment initiation and then every 2-3 cycles (6–12 
weeks), depending on the protocol. All radiographs were 
read in the Department of Radiology at MDACC and 
reviewed in the Department of Investigational Cancer 
Therapeutics tumor measurement clinic. Responses were 
categorized per Response Evaluation Criteria in Solid 
Tumors (RECIST) 1.0 [46] criteria and were reported as 
best response. Complete response (CR) was defined as 
the disappearance of all measurable and non-measurable 
disease; partial response (PR) was defined as at least 
a 30% decrease in the sum of the longest diameter of 
measurable target lesions; progressive disease (PD) was 
defined as at least a 20% increase in the sum of the longest 
diameter of measurable target lesions, or unequivocal 
progression of a non-target lesion, or the appearance 
of a new lesion; and stable disease (SD) was defined as 
neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD. A waterfall plot was used to 
illustrate the anti-tumor activity observed in patients 
evaluable for response.
Statistical analysis
Patient characteristics, including demographics, 
EGFR mutation status and prior treatment with an 
EGFR inhibitor were summarized using frequencies and 
percentages. Time to treatment failure (TTF) was defined 
as the time interval between the start of therapy and the 
date of disease progression or death, whichever occurred 
first. Patients who were alive and had not failed treatment 
were censored at the time of their last follow-up. The 
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Kaplan-Meier method [47] was used to estimate TTF and 
log-rank tests [48] were performed to compare subgroups 
of patients. All tests were two-sided, and P <0.05 was 
considered statistically significant. All statistical analyses 
were carried out using SPSS (version 19.0; SPSS, 
Chicago, IL, USA). 
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